company background image
CSCI logo

COSCIENS Biopharma NasdaqCM:CSCI Stock Report

Last Price

US$3.41

Market Cap

US$11.0m

7D

-3.9%

1Y

-66.7%

Updated

28 May, 2025

Data

Company Financials

COSCIENS Biopharma Inc.

NasdaqCM:CSCI Stock Report

Market Cap: US$11.0m

CSCI Stock Overview

A life science company, engages in developing and commercializing products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Columbia, the United Kingdom, and internationally. More details

CSCI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Earnings have declined by 24.9% per year over past 5 years

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

COSCIENS Biopharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for COSCIENS Biopharma
Historical stock prices
Current Share PriceCA$3.41
52 Week HighCA$11.10
52 Week LowCA$1.96
Beta1.85
1 Month Change8.80%
3 Month Change17.61%
1 Year Change-66.72%
3 Year Change-83.44%
5 Year Change-97.06%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

Aug 29

Aeterna slips ~10% after announcing date of reverse stock split

Jul 19

Shareholder Returns

CSCIUS BiotechsUS Market
7D-3.9%0.4%0.8%
1Y-66.7%-9.6%11.5%

Return vs Industry: CSCI underperformed the US Biotechs industry which returned -10.4% over the past year.

Return vs Market: CSCI underperformed the US Market which returned 11.3% over the past year.

Price Volatility

Is CSCI's price volatile compared to industry and market?
CSCI volatility
CSCI Average Weekly Movement15.4%
Biotechs Industry Average Movement12.1%
Market Average Movement8.0%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.2%

Stable Share Price: CSCI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CSCI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199040Anna Biehnwww.cosciensbio.com

COSCIENS Biopharma Inc., a life science company, engages in developing and commercializing products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Columbia, the United Kingdom, and internationally. The company lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications. It has a license agreement with NK MEDITECH Ltd.

COSCIENS Biopharma Inc. Fundamentals Summary

How do COSCIENS Biopharma's earnings and revenue compare to its market cap?
CSCI fundamental statistics
Market capUS$11.03m
Earnings (TTM)-US$17.56m
Revenue (TTM)US$9.03m
1.2x
P/S Ratio
-0.6x
P/E Ratio

Is CSCI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSCI income statement (TTM)
RevenueUS$9.03m
Cost of RevenueUS$4.76m
Gross ProfitUS$4.27m
Other ExpensesUS$21.83m
Earnings-US$17.56m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.58
Gross Margin47.26%
Net Profit Margin-194.50%
Debt/Equity Ratio0%

How did CSCI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 02:17
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COSCIENS Biopharma Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
Douglas LoeCantor Fitzgerald Canada Corporation
Charles DuncanCitizens JMP Securities, LLC